HHS awards $6.6M contract for surgical instruments, raising questions about competition and value

Contract Overview

Contract Amount: $66,070 ($66.1K)

Contractor: Qiagen, LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2026-04-15

End Date: 2027-04-14

Contract Duration: 364 days

Daily Burn Rate: $182/day

Competition Type: NOT COMPETED UNDER SAP

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: QIAGEN INC:1110297 [26-002891]

Place of Performance

Location: GERMANTOWN, MONTGOMERY County, MARYLAND, 20874

State: Maryland Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $66,070 to QIAGEN, LLC for work described as: QIAGEN INC:1110297 [26-002891] Key points: 1. The contract's value of $6.6 million warrants scrutiny for cost-effectiveness. 2. Limited competition raises concerns about potential overpricing and reduced innovation. 3. The fixed-price nature of the award may offer some cost certainty but could limit flexibility. 4. Performance risk appears moderate given the established nature of surgical instrument manufacturing. 5. This contract positions QIAGEN, LLC within the broader medical device and instrument sector. 6. The duration of 364 days suggests a need for ongoing procurement for sustained supply.

Value Assessment

Rating: fair

The contract value of $6.6 million for surgical instruments requires careful benchmarking against similar procurements. Without detailed line-item breakdowns or comparisons to market rates for specific instruments, assessing true value-for-money is challenging. The fixed-price nature provides some predictability, but the lack of competitive bidding could mean taxpayers are not receiving the most advantageous pricing. Further analysis of the specific instruments procured and their typical market costs is needed to definitively assess value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was not competed under simplified acquisition procedures, indicating a sole-source or limited competition award. The absence of a broad solicitation means that multiple potential suppliers were not given the opportunity to bid. This lack of competition can lead to higher prices and reduced incentive for the contractor to offer innovative solutions or the best possible terms. The specific justification for the sole-source award would be critical to understanding why other vendors were not considered.

Taxpayer Impact: Sole-source awards limit the government's ability to leverage market competition to secure lower prices. This can result in taxpayers paying more than necessary for goods and services, as the chosen contractor faces less pressure to be cost-competitive.

Public Impact

The primary beneficiaries are likely healthcare providers and patients who will receive necessary surgical instruments. The contract delivers essential medical supplies for surgical procedures, supporting patient care. The geographic impact is centered in Maryland, where the contractor is located. Workforce implications may include support for manufacturing and logistics jobs within QIAGEN, LLC.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competitive bidding may lead to inflated costs for taxpayers.
Sole-source nature limits opportunities for small businesses to compete for this contract.
Potential for vendor lock-in if alternatives are not actively sought in the future.

Positive Signals

Contract awarded to a known entity (QIAGEN, LLC), potentially indicating a reliable supplier.
Fixed-price contract offers some budget certainty for the agency.
Clear end date (2027-04-14) provides a defined period for the contract.

Sector Analysis

The surgical and medical instrument manufacturing sector is a critical component of the healthcare industry, encompassing a wide range of products from basic tools to complex diagnostic equipment. This contract falls within the broader medical device market, which is characterized by significant research and development, stringent regulatory requirements, and a mix of large established players and specialized smaller firms. Spending in this area is consistently high across federal agencies, particularly within health-focused departments like HHS, reflecting the ongoing need for medical supplies.

Small Business Impact

The contract data indicates that small business participation was not a stated requirement or outcome (ss: false, sb: false). As a sole-source award, it bypasses the typical competitive processes where small business set-asides are often implemented. This means there are likely no direct subcontracting opportunities mandated for small businesses under this specific award. The impact on the small business ecosystem is neutral to negative, as opportunities were not actively created or promoted for them through this procurement.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services (HHS) and its respective contracting officers and program managers. Accountability measures are inherent in the contract terms, particularly the fixed-price structure and delivery schedule. Transparency could be enhanced by making the justification for the sole-source award publicly available and by reporting on performance metrics. Inspector General jurisdiction would apply if any fraud, waste, or abuse were suspected.

Related Government Programs

Medical Supplies Procurement
Surgical Equipment Contracts
Department of Health and Human Services Contracts
National Institutes of Health Procurements
Medical Instrument Manufacturing

Risk Flags

Lack of Competition
Potential for Overpricing
Limited Transparency on Justification
No Small Business Set-Aside Identified

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $66,070 to QIAGEN, LLC. QIAGEN INC:1110297 [26-002891]

Who is the contractor on this award?

The obligated recipient is QIAGEN, LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $66,070.

What is the period of performance?

Start: 2026-04-15. End: 2027-04-14.

What is the specific justification for awarding this contract on a sole-source basis to QIAGEN, LLC?

The provided data indicates the contract was 'NOT COMPETED UNDER SAP' (Simplified Acquisition Procedures), suggesting it was either a sole-source award or competed under very limited circumstances not detailed here. Typically, sole-source justifications are based on factors such as the unique capabilities of a single contractor, urgent and compelling needs where only one source can reasonably fulfill the requirement, or specific follow-on work to a previously awarded contract. Without the official justification document (e.g., a Justification and Approval - J&A), it is impossible to determine the precise reason. This lack of competition is a key area for further investigation as it directly impacts price discovery and potential value for taxpayers.

How does the $6.6 million contract value compare to similar procurements for surgical instruments by federal agencies?

Benchmarking the $6.6 million contract value requires comparing it against procurements for comparable surgical instruments, considering factors like quantity, specific types of instruments, and contract duration. Publicly available contract databases (like FPDS or SAM.gov) can be queried for similar awards. However, without knowing the exact nature of the instruments QIAGEN, LLC is supplying, a precise comparison is difficult. Generally, large dollar values for non-competed contracts warrant closer examination to ensure they align with market rates and represent fair value. If this amount is significantly higher than competitively awarded contracts for similar items, it suggests potential overpricing due to the lack of competition.

What are the potential risks associated with a sole-source award for essential medical supplies?

Sole-source awards for essential medical supplies carry several risks. Firstly, the lack of competition can lead to higher prices than might be achieved through a competitive bidding process, meaning taxpayers could be overpaying. Secondly, it reduces the incentive for the sole contractor to innovate or improve efficiency, as they face no direct market pressure from competitors. Thirdly, it creates a dependency on a single supplier, which can be problematic if that supplier experiences production issues, quality control problems, or decides to significantly increase prices in the future. Finally, it limits opportunities for other capable businesses, including small businesses, to enter the market or expand their footprint.

What is QIAGEN, LLC's track record with federal contracts, particularly with HHS and NIH?

QIAGEN, LLC is a known entity in the life sciences and diagnostics sector. Their track record with federal agencies, including HHS and its sub-agency NIH, would need to be reviewed through contract databases. This review should assess the volume and value of past contracts, their performance history (if available through contract award data or past performance evaluations), and any history of contract disputes or issues. A positive track record with reliable delivery and quality could lend some confidence to this award, but it does not negate the concerns raised by the sole-source nature of this specific procurement.

What specific types of surgical and medical instruments are included in this $6.6 million contract?

The provided data classifies the contract under NAICS code 339112 (Surgical and Medical Instrument Manufacturing) but does not specify the exact types of instruments. This information is crucial for a thorough analysis. Understanding whether these are routine consumables, specialized surgical tools, diagnostic equipment, or components is necessary to assess the contract's criticality, potential for competition, and appropriate value benchmarks. Without this detail, the $6.6 million figure remains abstract and difficult to evaluate against market norms or alternative suppliers.

What is the historical spending pattern for surgical and medical instruments by the National Institutes of Health (NIH)?

Analyzing NIH's historical spending on surgical and medical instruments provides context for the current $6.6 million award. This involves examining trends over several fiscal years, identifying major contract vehicles, key suppliers, and average award values. Understanding NIH's typical procurement strategies (e.g., reliance on GSA schedules, competitive bidding, sole-source awards) and the overall market size for these goods within NIH can help determine if this contract is an outlier or part of a consistent spending pattern. Significant deviations or a pattern of sole-source awards in this category would warrant further investigation into procurement practices.

Industry Classification

NAICS: Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing

Product/Service Code: MAINT, REPAIR, REBUILD EQUIPMENT › MAINT, REPAIR, REBUILD OF EQUIPMENT

Competition & Pricing

Extent Competed: NOT COMPETED UNDER SAP

Solicitation Procedures: SIMPLIFIED ACQUISITION

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 19300 GERMANTOWN RD, GERMANTOWN, MD, 20874

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $66,070

Exercised Options: $66,070

Current Obligation: $66,070

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Timeline